Y Intercept (Hong Kong) LTD Protalix Bio Therapeutics, Inc. Transaction History
Y Intercept (Hong Kong) LTD
- $1.44 Billion
- Q4 2024
A detailed history of Y Intercept (Hong Kong) LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Y Intercept (Hong Kong) LTD holds 18,818 shares of PLX stock, worth $43,657. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,818Holding current value
$43,657% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
4.58MCall Options Held
40.9KPut Options Held
5.3K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.12MShares$2.59 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL732KShares$1.7 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny388KShares$899,9760.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$772,9560.0% of portfolio
-
Gsa Capital Partners LLP London, X0306KShares$709,3370.04% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $115M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...